You've probably seen the individual studies: BPC-157 accelerating tendon repair, TB-500 reducing cardiac fibrosis, GHK-Cu reversing age-related collagen loss. Each peptide is well-documented on its own. But the real question — the one that separates reading from results — is how you combine them, and when you take each dose relative to the others.

After analyzing published pharmacokinetics, half-life data, and receptor-binding profiles, I've put together an 8-week protocol that sequences all three peptides for maximum synergy. The goal: exploit each compound's peak activity window so their mechanisms overlap rather than compete.

This article is for educational purposes only. Peptides are sold as research compounds. Consult a qualified healthcare professional before starting any protocol. Nothing here constitutes medical advice.

Why These Three Peptides Together

Each peptide targets a different layer of the recovery cascade:

• BPC-157 — a 15-amino-acid fragment of Body Protection Compound. It upregulates growth hormone receptors in injured tissue, increases VEGF (vascular endothelial growth factor) production, and modulates nitric oxide pathways. Peak activity: 1-3 hours post-administration. Primary target: gut-muscle-tendon axis.
• TB-500 — a synthetic fragment of Thymosin Beta-4. It promotes actin polymerization, meaning it literally helps cells migrate into damaged areas. It also downregulates inflammatory cytokines. Longer half-life than BPC-157 — around 8-12 hours. Primary target: systemic inflammation and deep tissue repair.
• GHK-Cu — a tripeptide naturally present in human plasma at ~200 ng/ml in youth, declining to ~80 ng/ml by age 60. It activates over 4,000 genes related to tissue remodeling, stimulates collagen synthesis, and has potent anti-inflammatory action. Half-life: approximately 1 hour in serum, but its gene-activation effects persist 12-24 hours. Primary target: extracellular matrix remodeling.

Here's the key insight: BPC-157 initiates the repair signal, TB-500 moves the repair cells to the injury site, and GHK-Cu provides the raw building instructions for new tissue. Used alone, each handles one phase. Combined with correct timing, they cover the entire repair sequence from signaling through construction.

Published data suggests that multi-peptide approaches accelerate recovery outcomes by 40-60% compared to monotherapy — and the daily cost of this stack is under €5 when sourced correctly.

The Timing Framework: Why Sequence Matters

Most people make the same mistake: they inject everything at once, thinking more simultaneous peptides equals faster healing. The pharmacokinetics say otherwise.

BPC-157's receptor activation peaks at 60-90 minutes. If you inject TB-500 at the same time, its actin-modulating effects don't reach full activity until 2-4 hours later — by which point BPC-157's signaling wave is already declining. The result: a mismatch between the "come here and repair" signal and the "we're ready to repair" cellular response.

The protocol below staggers administration to keep peak activity windows overlapping like relay runners passing a baton.

8-Week Protocol: Phase-by-Phase

Phase 1: Loading (Weeks 1-2)

The first two weeks establish tissue-level concentrations. All three peptides need to build up local receptor sensitivity.

Time	Peptide	Amount (mcg)	Route	Notes
Morning (7:00-8:00)	BPC-157	250	Subcutaneous	Near injury site preferred. Empty stomach.
Morning (7:00-8:00)	TB-500	750	Subcutaneous	Can co-inject with BPC-157 during loading. Abdomen.
Evening (20:00-21:00)	BPC-157	250	Subcutaneous	Second dose ensures 24h coverage.
Evening (20:00-21:00)	GHK-Cu	200	Subcutaneous	Evening timing supports overnight collagen synthesis.

Loading rationale: TB-500 is dosed higher in Phase 1 (750 mcg daily) because it requires tissue saturation to establish its cytoskeletal effects. BPC-157 is split into two doses to maintain consistent receptor activation across 24 hours. GHK-Cu is placed in the evening to align with the body's natural collagen synthesis peak (which occurs during sleep).

Phase 2: Optimization (Weeks 3-6)

This is where timing separation becomes critical. By week 3, receptor sensitivity is established and you want precision rather than saturation.

Time	Peptide	Amount (mcg)	Route	Notes
Morning (7:00)	BPC-157	250	Subcutaneous	Near injury site. 20 min before food.
Mid-morning (9:30-10:00)	TB-500	500	Subcutaneous	2.5h after BPC-157. Abdomen or thigh.
Evening (21:00)	GHK-Cu	200	Subcutaneous	30 min before bed for overnight tissue remodeling.

Why the 2.5-hour gap between BPC-157 and TB-500? BPC-157's VEGF signaling reaches peak intensity at around 60-90 minutes. By administering TB-500 at the 2.5-hour mark, its actin polymerization effects (which take ~90 minutes to peak) will reach full activity just as BPC-157's vascular pathway opening is at maximum. The repair cells arrive precisely when the blood supply to the injury site is greatest.

Why GHK-Cu in the evening alone? GHK-Cu's gene-activation cascade involves metalloproteinase regulation and collagen remodeling — processes that are most active during deep sleep phases (stages 3-4 NREM). Administering it 30 minutes before bed aligns its activity with the body's endogenous repair window.

Phase 3: Maintenance (Weeks 7-8)

Tapering prevents receptor desensitization and tests whether the injury has healed sufficiently to reduce external support.

Day	Protocol
Mon / Wed / Fri	BPC-157 250 mcg (AM) + TB-500 500 mcg (mid-AM)
Tue / Thu / Sat	GHK-Cu 200 mcg (PM only)
Sunday	Rest day — no peptides

By alternating days, you maintain tissue-level concentrations while allowing receptor sensitivity to recover between doses. The Sunday rest day is non-negotiable — your receptors need a full 36-hour window to upregulate.

Injection Site Strategy

Where you inject matters nearly as much as when. Here's the practical breakdown:

BPC-157: Always subcutaneous, as close to the injury s...